E. faecium SF68®: a model for EFFICACY & SAFETY for Pharmaceutical Probiotics

Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce the publication of a comprehensive review on its proprietary Probiotic Active Ingredient E. faecium SF68® (SF68®).

In an article, published in the Scientific Journal “Beneficial Microbes”, extensive information is provided on the efficacy and safety of SF68® supported by well-established scientific and surveillance data.

Exactly 50 years after the discovery of the probiotic strain, this review provides an overview on the huge amount of scientific information available regarding efficacy and safety of our Probiotic.

“This article is in line with our experience of over thirty years distribution to patients in different markets where SF68® has gained importance thanks to its beneficial effects for the prevention and treatment of gastrointestinal disorders without any adverse event”, confirms Gabriel Haering, CEO of Cerbios.

In fact, SF68® has been used since decades both for human and animal health applications and is considered as one of the best characterized probiotic with respect to efficacy and safety with an exceptionally long history of safe use in probiotic therapy.

The review is entitled “Enterococcus faecium SF68® as a model for Efficacy and Safety evaluation of pharmaceutical probiotics”. The authors are experts in the field of probiotics with profound know-how on Enterococci and, in particular, on SF68®. Among them are the renowned scientists Prof. Wilhelm Holzapfel and Prof. Bruno Pot.

The original publication is available at this LINK

About SF68®
SF68® is a probiotic active ingredient of pharmaceutical quality produced by Cerbios-Pharma SA and is contained in pharmaceutical probiotics such as Bioflorin®, Newflora®, Neoflor®, Diaflor® and Ventrux®.
It is approved as a pharmaceutical probiotic by the health authorities of different countries, starting from Switzerland in 1979. Besides its application as pharmaceutical probiotic it is approved by EFSA under the name of the strain deposit E. faecium NCIMB 10415 as a “gut flora stabiliser” for various animal categories.

About Cerbios-Pharma SA
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Cerbios’ is a global leading supplier of a portfolio of Generic APIs primarily used for the treatment of Respiratory and Dermatological disorders as well as in Oncology.
Exclusive, CDMO services are offered for the development and manufacturing of HPAIs as well as for Biological products including monoclonal antibodies, recombinant proteins, Antibody Drug Conjugates (ADCs) and pharma probiotics.
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.

For more information please contact
Martin Aeschbacher
Senior Manager
M&S Biological Division
info@cerbios.ch

Cerbios-Pharma SA
Via Pigino 6
CH - 6917 Barbengo/Lugano
Phone +41 (0) 91 985 63 11
Fax +41 (0) 91 985 63 25
email info@cerbios.ch